Adagene - About the company
Adagene is a public company based in Suzhou (China), founded in 2012 by Peter Luo. It operates as a Developer of immunotherapy for the treatment of cancer. Adagene has raised $155M in funding from investors like WuXi AppTec, Eight Roads Ventures and F-Prime Capital. The company has 3223 active competitors, including 1106 funded and 767 that have exited. Its top competitors include companies like Jazz Pharmaceuticals, Moderna and Sana Biotechnology.
Company Details
Developer of immunotherapy for the treatment of cancer. It is developing antibodies which include ADG106 which is an agonist for CD137 in metastatic solid tumors, ADG126 targets CTLA4 for cancer therapy, and aADG116 targets epitope of CTLA4 in metastatic solid tumors and relapsed/refractory non-Hodgkin’s lymphoma.
- Website
- www.adagene.com/
- Email ID
- *****@adagene.com
- Phone Number
- +86 **********
- Registered Address
- San Francisco, California
Key Metrics
Founded Year
2012
Location
Suzhou, China
Stage
Public
Total Funding
$155M in 5 rounds
Latest Funding Round
Investors
Ranked
49th among 3223 active competitors
Employee Count
83 as on Mar 31, 2026
Similar Companies
Exit Details
Public
Legal entities associated with Adagene
Adagene is associated with 1 legal entity given below:
Legal Entity Name | Date of Incorporation | Revenue | Latest Employee Count | Documents |
|---|---|---|---|---|
ADAGENE INCORPORATED CIN: 822877710 , United States, Active | - | 15 (As on Dec 31, 2020) | - |
Adagene's IPO details
Adagene got listed on Feb 09, 2021.
Click here to take a look at Adagene's IPO in detail
Sign up to download Adagene's company profile
Adagene's funding and investors
Adagene has raised a total funding of $155M over 5 rounds. Its first funding round was on Dec 08, 2014. Its latest funding round was a Post IPO round on Jul 01, 2025 for $*****. 1 investor participated in its latest round. Adagene has 14 institutional investors.
Here is the list of recent funding rounds of Adagene:
Filter this list
Filter this listDate of Funding | Funding Amount | Round Name | Post-Money Valuation | Revenue Multiple | Lead Investors | Other Investors |
|---|---|---|---|---|---|---|
Jul 01, 2025 | 4930291 | Post IPO | 6579924 | 8008758 | 8846845 | 7099252 |
Jan 09, 2020 | 4518485 | Series D | 7454937 | 7850969 | 1521683 | |
Mar 26, 2018 | 6787727 | Series C | 8205931 | 9072232 |
Access funding benchmarks and valuations. Sign up today!View details of Adagene's funding rounds and investors
Adagene's founders and board of directors
Founder? Claim ProfileHere are the details of Adagene's key team members:
- Peter Luo: Founder & CEO of Adagene and founder of 1 other company.
View details of Adagene's Founder profiles and Board Members
Adagene's employee count trend
Adagene has 83 employees as of Mar 26. Here is Adagene's employee count trend over the years:
Uncover Adagene's growth story! Sign up today!
Access Tracxn on any website
Install Tracxn ExtensionOur Google Chrome extension lets you view company details while browsing their websites
Adagene's Competitors and alternates
Top competitors of Adagene include Jazz Pharmaceuticals, Moderna and Sana Biotechnology. Here is the list of Top 10 competitors of Adagene, ranked by Tracxn score:
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!
Rank | Company Details | Short Description | Total Funding | Investors | Tracxn Score |
|---|---|---|---|---|---|
1st |  Jazz Pharmaceuticals 2003, Dublin (Ireland), Public | Developer of novel biopharmaceutical medicines for unmet medical needs | $265M | 82/100 | |
2nd |  Moderna 2010, Cambridge (United States), Public | Developer of mRNA-based therapeutics for a wide range of diseases | $2.78B | 80/100 | |
3rd |  Sana Biotechnology 2018, Seattle (United States), Public | Developer of genetically engineered cell therapies for multiple disorders | $821M | 75/100 | |
4th | C4 Therapeutics 2016, Cambridge (United States), Public | Developer of small molecule drugs for treating cancer | $223M | 74/100 | |
5th | Juno Therapeutics 2013, Seattle (United States), Acquired | Global biopharmaceutical company discovering, developing, and delivering innovative medicines | $317M | 74/100 | |
6th |  Advanced Accelerator Applications 2002, Saint Genis Pouilly (France), Acquired | Novartis company, developing molecular nuclear medicine theranostics | $56.1M | 73/100 | |
7th | Blueprint Medicines 2008, Cambridge (United States), Acquired | Developer of selective kinase inhibitors for patients with genomically defined cancers | $115M | 72/100 | |
8th | _1548135965397.png?devicePixelRatio=2&height=30&width=30){kind=logo} Kronos Bio 2017, San Mateo (United States), Acquired | Developer of small molecule based therapeutics for cancer treatment | $271M | 72/100 | |
9th |  Regeneron Pharmaceuticals 1988, Tarrytown (United States), Public | Developer of antibodies for the treatment of cancer, eye diseases, inflammatory diseases & others | - | 72/100 | |
10th |  BeiGene 2010, Cambridge (United States), Public | Developer of targeted and immune-oncology drugs against cancer | $172M | 72/100 | |
49th | Developer of immunotherapy for the treatment of cancer | $155M | 67/100 |
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!Looking for more details on Adagene's competitors? Click here to see the top ones
Adagene's Investments and acquisitions
Adagene has made no investments or acquisitions yet.
Reports related to Adagene
Here is the latest report on Adagene's sector:
News related to Adagene
Filter this listMedia has covered Adagene for a total of 13 events in the last 1 year, 4 of them have been about company updates and 2 about partnerships.
•
•
Adagene Licenses SAFEbody Tech to Third Arc Bio for Masked CD3 T Cell EngagersGlobeNewswire•Nov 13, 2025•Third Arc Bio, Adagene
•
•
Adagene Expands SAFEbody® Collaboration and License with Exelixis for Antibody-Drug ConjugateGlobeNewswire•Sep 16, 2025•Adagene, Exelixis
•
Adagene Appoints Immuno-Oncology Pioneer Axel Hoos as Executive AdvisorGlobeNewswire•Sep 03, 2025•Adagene
•
Adagene Reports Six Months 2025 Financial Results and Corporate UpdatesGlobeNewswire•Aug 13, 2025•Adagene
•
Ropes & Gray Advises Sanofi in Adagene Strategic Investment Up to $25 MillionLegal Desire•Jul 21, 2025•Sanofi, Adagene
•
Adagene Announces Regulatory Update on Muzastotug Clinical Development Plan Following FDA MeetingGlobeNewswire•Jul 15, 2025•Adagene
•
Adagene and ConjugateBio Partner to Develop Novel Antibody Drug ConjugateGlobeNewswire•Jul 08, 2025•Adagene, ConjugateBio
•
Adagene shares rise after $25 million strategic investment from SanofiInvesting•Jul 01, 2025•Adagene, Sanofi
Get curated news about company updates, funding rounds, M&A deals and others. Sign up today!Are you a Founder ?
FAQs about Adagene
Explore our recently published companies
- EG Bookkeeping - Indianapolis based, 2015 founded, Unfunded company
- Rapidlogger - Stafford based, 2008 founded, Unfunded company
- Temple Baptist Church - Dalton based, 1969 founded, Unfunded company
- Bidias Company - Brooklyn Park based, 2008 founded, Unfunded company
- Innovative Implements - Chicago based, 2016 founded, Unfunded company
- Ieng Solutions - Coventry based, 2016 founded, Unfunded company
